<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="urgent need for therapeutics. Through a series of drug repurposing" exact="screening" post="campaigns, niclosamide, an FDA-approved anthelminthic drug, was found to"/>
 <result pre="of niclosamide and highlight its potential clinical use in the" exact="treatment" post="of COVID-19. niclosamide broad antiviral agents coronavirus SARS-CoV MERS-CoV"/>
 <result pre="urgent to search for other effective inhibitors for the potential" exact="treatment" post="of COVID-19. Drug repurposing screens have emerged as an"/>
 <result pre="at the end of January 2020.25,26 The lack of effective" exact="treatment" post="for coronavirus infections poses a great challenge to clinical"/>
 <result pre="viral antigen synthesis at a concentration of 1.56 μM after" exact="screening" post="a small marketed drug library.27 Niclosamide suppressed the cytopathic"/>
 <result pre="mosquito-borne flavivirus that is transmitted primarily by Aedes mosquitoes. ZIKV" exact="infection" post="can cause infants to be born with microcephaly and"/>
 <result pre="such as Guillain–Barré syndrome, neuropathy, and myelitis.34−38 Outbreaks of ZIKV" exact="infection" post="have been recorded several times (2015 in Brazil, the"/>
 <result pre="emergency. Xu et al. used caspase-3 activity as the primary" exact="screening" post="assay and discovered niclosamide as a potent inhibitor of"/>
 <result pre="RNA level.22 The time-of-addition studies indicated that niclosamide inhibits ZIKV" exact="infection" post="at a postentry stage, probably in a viral RNA"/>
 <result pre="as a potent anti-ZIKV inhibitor through an independent quantitative high-throughput" exact="screening" post="(qHTS) campaign and found that niclosamide directly inhibits flavivirus"/>
 <result pre="that of its derivatives nitazoxanide and tizoxanide.45−47 However, chronic HCV" exact="infection" post="requires long-term (several months) antiviral treatment, which may make"/>
 <result pre="weak lipophilic acid and was reported to inhibit pH-dependent HRV" exact="infection" post="with low micromolar IC50 values; it suppresses HRV entry"/>
 <result pre="resulting in a lymphoproliferative disorder known as infectious mononucleosis. EBV" exact="infection" post="was also found to be associated with the development"/>
 <result pre="daily doses of 2 g of niclosamide each, while the" exact="treatment" post="of Hymenolepis nana infection requires one or several 5–7"/>
 <result pre="g of niclosamide each, while the treatment of Hymenolepis nana" exact="infection" post="requires one or several 5–7 day courses of niclosamide"/>
 <result pre="toxic effects in human.10 Through a series of drug repurposing" exact="screening" post="campaigns, niclosamide was found to be effective against a"/>
 <result pre="proteolytic processing and is indispensable for viral replication and the" exact="infection" post="process.6 Recently, the high-resolution crystal structure of SARS-CoV-2 3CL"/>
 <result pre="of COVID-19 by targeting SARS-CoV-2 3CL protease via high-throughput virtual" exact="screening" post="of compound libraries or existing drug libraries for drug"/>
 <result pre="main proteinase (Mpro) of SARS-CoV-2 may facilitate the in silico" exact="screening" post="of existing drugs for drug repurposing or the identification"/>
 <result pre="COVID-19 and save hundreds of patient lives.7,64,65 Very recently, through" exact="screening" post="the existing antiviral drugs, three broad antiviral agents (nitazoxanide,"/>
 <result pre="RdRp RNA-dependent RNA polymerase CPE cytopathic effect qHTS quantitative high-throughput" exact="screening" post="(qHTS) EC50 half maximal effective concentration IC50 half maximal"/>
 <result pre="SongH.; TangH. (2016) Identification of small-molecule inhibitors of Zika virus" exact="infection" post="and induced neural cell death via a drug repurposing"/>
 <result pre="NeilJ.; GhawchéF. (2016) Guillain-Barré Syndrome outbreak associated with Zika virus" exact="infection" post="in French Polynesia: a case-control study. Lancet387, 1531–1539. 10.1016/S0140-6736(16)00562-6.26948433"/>
 <result pre="Antiviral Res.138, 68–78. 10.1016/j.antiviral.2016.12.002.27939840 JonesW. E. (1979) Niclosamide as a" exact="treatment" post="for Hymenolepis diminuta and Dipylidium caninum infection in man."/>
 <result pre="Niclosamide as a treatment for Hymenolepis diminuta and Dipylidium caninum" exact="infection" post="in man. Am. J. Trop. Med. Hyg.28, 300–302. 10.4269/ajtmh.1979.28.300.572147"/>
</results>
